Clinical trials
Second Line Treatment clinical trials
Below are recruiting second line treatment clinical trials, each written for real people, not researchers. We’re tracking 156 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07091019Recruiting
CML patient experience study on standard TKI therapy
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Birmingham, AlabamaAges 18–100 - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Phoenix, ArizonaAges 18 years+ - NCT04278222RecruitingPhase 2
Anlotinib plus immunotherapy for advanced stomach cancer
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
ShanghaiAges 18 years+ - NCT04378647RecruitingPhase 2
Brentuximab before transplant for relapsed CD30 Hodgkin lymphoma
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
Barcelona, BarceolnaAges 18–65 - NCT04467723RecruitingPhase 1/Phase 2
Atezolizumab plus pirfenidone for advanced lung cancer
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Fairway, KansasAges 18 years+ - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05768503RecruitingPhase 3
Test new drugs after colorectal cancer chemotherapy
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
Hefei, AnhuiAges 18–75 - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT06020755RecruitingPhase 2
Toripalimab plus actinomycin-D for GTN with FIGO score 7
This trial tests a combination of two drugs — toripalimab (an immunotherapy) and actinomycin-D (chemotherapy) — as the first treatment for a specific type of pregnancy-related tumor (GTN) with a FIGO score of 7. The goal is to see if this combination works better than standard treatment.
Beijing, Beijing MunicipalityAges 18–60 - NCT06028672Recruiting
Immunotherapy plus chemotherapy for moderate-risk GTN
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (actinomycin-D) as the first treatment for gestational trophoblastic neoplasia (GTN) with a FIGO score of 5-6. It may help patients whose disease is at a moderate risk level.
Beijing, Beijing MunicipalityAges 18–60 - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06202001RecruitingPhase 1/Phase 2
Three-drug combo for metastatic colorectal cancer as second treatment
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
BeijingAges 18–70 - NCT06213311RecruitingPhase 2
CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Houston, TexasAges 18 years+ - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06267781Recruiting
MS progression and immune cells after bone marrow transplant and other therapies
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
MilanAges 18 years+ - NCT06356584RecruitingPhase 2
A drug combination with or without radiation for advanced colorectal cancer
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
Jinan, ShandongAges 18–75 - NCT06363006RecruitingPhase 1
Cardonizumab plus TKI for advanced liver cancer after prior treatment
This trial tests a combination of an immunotherapy drug (Cardonizumab) and a targeted therapy pill (TKI) for people with advanced liver cancer whose prior treatment has stopped working. The goal is to see if this second-line combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75 - NCT06509945Recruiting
Donor stem cell transplant for high-risk T-cell lymphoma
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70
Hear when a new Second Line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for second line treatment?
- Yes. Clin2 currently lists 156 recruiting second line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a second line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a second line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.